

Merck invests ~€25 M in BioReliance® testing facility to support drug product release in Europe

July 20, 2026 | News

New 2,000-square-meter facility expands Merck's global testing network



Merck, a leading science and technology company, has opened a new €25 million BioReliance® testing facility at its global headquarters in Darmstadt, Germany. The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical companies developing and commercializing therapies in Europe.

The 2,000-square-meter facility is designed to help customers meet European requirements for in-region drug substance and drug product release testing and expands the company's ability to support customers from drug development through commercialization.

The site will also offer Good Manufacturing Practice (GMP)-compliant stability studies for monoclonal antibodies and cell therapies, addressing the growing demand for biologics testing across Europe. The facility will employ a growing team with headcount projected to expand significantly over the next few years to support client demand.

Located close to major clinical trial sites in Germany, France, Spain, the Netherlands, Belgium and Italy, the Darmstadt facility is strategically positioned to support biopharmaceutical companies seeking to release drug products into European markets. By adding these capabilities in the heart of Europe, Merck is strengthening its support for customers managing increasingly complex development, quality and regulatory requirements.